Lilly Strikes $1.2B deal to Acquire Ventyx and Bolster Oral Anti-inflammatory Drug Pipeline

Indianapolis, IN, January 7, 2026 (PR Newswire) -- Eli Lilly and Company announced it will acquire Ventyx Biosciences in an all-cash transaction valued at approximately $1.2 billion, expanding its presence in inflammatory-mediated diseases. The deal brings Ventyx’s clinical-stage portfolio of oral small molecules, including NLRP3 inhibitors designed to address chronic inflammation across cardiometabolic, neurodegenerative, and autoimmune conditions. Lilly will pay $14.00 per share, representing a premium of about 62%, with closing expected in the first half of 2026 subject to customary approvals.

Read full article here.